Jaguar Health, Inc.
JAGX evidence brief
What we can confirm
- BioSniper Score:
- 7.3 / 10
- Market Cap:
- $1.6M
- Lead Asset:
- canalevia-ca1 (Approved)
What it means
What to watch
Prepared research question
What matters most for JAGX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · JAGX
Jaguar Health, Inc. (JAGX) is a biopharmaceutical company focused on developing and commercializing crofelemer-based therapies for rare gastrointestinal diseases, with an approved product for HIV-associated diarrhea and a late-stage pipeline targeting microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF).
Key risk: Low cash runway
BioSniper Score
Based on 4 of 6 signals
Market Cap
$1.6M
Cash Runway
—
Lead Asset
canalevia-ca1 (Approved)
Next Catalyst
Patent_Expiry · Oct 31, 2031Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 1 catalyst for Jaguar Health, Inc..
Jaguar Health, Inc. (JAGX) is a biopharmaceutical company focused on developing and commercializing crofelemer-based therapies for rare gastrointestinal diseases, with an approved product for HIV-associated diarrhea and a late-stage pipeline targeting microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF).
- Cash and equivalents of $3.8M and total revenue of $1.2M as of 2026-06-30 [sec].
- Pivotal Phase 3 trial of crofelemer powder for MVID is ongoing, with all randomized pediatric patients having entered the extension phase [news · published 2026-09-10].
- Company targets an NDA filing for the MVID indication in mid-2027 [news · published 2026-09-22].
- FDA granted a waiver of the PDUFA fee for Mytesi for the 2027 fiscal year [news · published 2026-09-22].
- Jaguar secured $18M in non-dilutive capital via a partnership with Future Pak, LLC for marketing Mytesi and Canalevia-CA1 [news · published 2026-08-20].
What works
- Crofelemer has a novel mechanism of action (modulating intestinal chloride ion secretion) and is already approved as Mytesi for noninfectious diarrhea in HIV/AIDS patients, providing a commercial foothold [pipeline].
- The company has secured non-dilutive capital ($18M) through the Future Pak partnership, reducing near-term dilution risk [news · published 2026-08-20].
- FDA fee waivers and Orphan Drug status for crofelemer indicate regulatory support for the rare disease program [news · published 2026-09-22].
What to weigh
- Cash position is low ($3.8M as of 2026-06-30) relative to the costs of a global Phase 3 trial and planned NDA filing [sec].
- Total revenue is modest ($1.2M as of 2026-06-30) and has reportedly declined 60% year-over-year, raising questions about commercial sustainability [sec][news · published 2026-08-20].
- The pivotal MVID trial is still ongoing, and the NDA filing is not expected until mid-2027, leaving a long runway before potential new product revenue [news · published 2026-09-10].
From the filings
Quoted directly from source documents.
NDA filing target for MVID is mid-2027
“targeting an NDA filing for MVID mid-2027”
News · September 22, 2026
Catalyst timeline
- 2031-10-31 · Patent_Expiry · CROFELEMER — Patent_Expiry: NDA202292 — Patent expiry for crofelemer (Mytesi) could open the door to generic competition after this date.
Risks & what to watch (3)›
Key risks
- Low cash runway — Cash of $3.8M as of 2026-06-30 may be insufficient to fund ongoing Phase 3 trial and NDA preparation without additional financing [sec].
- Revenue decline — Total revenue of $1.2M as of 2026-06-30 and a reported 60% decline raise concerns about commercial viability [sec][news · published 2026-08-20].
- Clinical trial execution risk — The pivotal MVID trial is ongoing with no reported completion date; delays could push NDA filing beyond mid-2027 [news · published 2026-09-10].
What to watch
- Progress of the MVID pivotal trial and whether it meets endpoints to support NDA filing [news · published 2026-09-10].
- Cash position and any new financing or partnership announcements given the low $3.8M balance [sec].
- Revenue trajectory of Mytesi and Neonorm Dog to assess commercial execution [news · published 2026-08-26].
- Regulatory milestones, including FDA feedback on the MVID NDA and any updates on SBS-IF program [news · published 2026-09-22].
Sources: News · Pipeline · Generated October 5, 2026 · How we verify sources →
Run Jaguar Health, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Jaguar Health, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
0% dilution
Lead: Approved
4 candidates
1 upcoming, next in ~1843d
No insider transactions in the last 180 days
Catalysts
Pipeline
Financials
Short Interest
as of Apr 30, 2026- % of float
- 4.6%
- Days to cover
- 1.2
- Shares short
- 17,139
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
JAGX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Jaguar Health, Inc.?
Jaguar Health, Inc. (JAGX) is a biopharmaceutical company focused on developing and commercializing crofelemer-based therapies for rare gastrointestinal diseases, with an approved product for HIV-associated diarrhea and a late-stage pipeline targeting microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF).
What is Jaguar Health, Inc.'s lead drug candidate?
Jaguar Health, Inc.'s most advanced tracked candidate is canalevia-ca1 (Approved) for chemotherapy-induced diarrhea (CID) in dogs.
What is Jaguar Health, Inc.'s next catalyst?
Jaguar Health, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA202292" — expected October 31, 2031.
Who is the CEO of Jaguar Health, Inc.?
Ms. Lisa A. Conte is the chief executive officer of Jaguar Health, Inc. (JAGX).
Where is Jaguar Health, Inc. headquartered?
Jaguar Health, Inc. (JAGX) is headquartered in San Francisco, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.